Characteristics and Results of the Management of Diffuse Large B-Cell Lymphomas: The Experience of Côte d'Ivoire

Advances in Hematology

Clinical Study

Ibrahima Sanogo¹  Gustave K. Koffi¹  Mozart Konan¹  Paul Kouéhion¹  Mamadou Y. Sekongo¹  Roméo Ayémou¹  N'Dogomo Meité¹  Clotaire D. Nanho¹  Emeraude N'dhatz¹  Boidy Kouakou¹  Aïssata Tolo Diebkilé¹ 

[1] Department of Clinical Hematology, Yopougon Teaching Hospital, P.O. Box 632, Abidjan 21, Cote d'Ivoire

Others  :  1269245
DOI  :  10.1155/2012/945138

 received in 2012-01-17, accepted in 2012-03-27,  发布年份 2012

【 摘 要 】

Diffuse large B-cell lymphomas have been little studied in black Africans. The purpose of our study was to determine the characteristics and results of the management of these lymphomas. Patients and Methods. In a descriptive and analytic retrospective study we studied the medical records of 63 patients with diffuse large B-cell lymphoma hospitalized during the period from 1991 to 2007. The diagnosis was made after lymph node or organ biopsy. Response to treatment, OS, PFS, and toxicity were studied. The complete response has been analyzed univariate and multivariate analysis. Results. The median age was 42 years. The sex ratio was 2. The HIV serology was positive in 11 cases, and 8 patients had antiretroviral therapy. In 71% the lymphoma was at stages III and IV of Ann Arbor. IPI was ≥3 in 65%. Complete remission was achieved in 43%. Only 43% of patients had had a good compliance. Progression-free survival at 3 years was 32%, and overall survival at 3 years was 50%. 13% of patients were lost to follow up, and 51% of them died. In terms of analysis the complete remission rate was influenced by the stage of Ann Arbor (P<0.0001), biological b symptoms (P<0.01), the IPI (P<0.0001), and the socioeconomic standing (P=0.001). In multivariate analysis, only IPI and stage of Ann Arbor influence the complete remission.

【 授权许可】

CC BY   
Copyright © 2012 Aïssata Tolo Diebkilé et al. 2012

【 图 表 】

Figure 1

【 参考文献 】

• [1]R. Bouabdallah, J. A. Gastaut. (2005). Lymphomes malins. Hématologie clinique et biologique:339-350. DOI: 10.1097/CCO.0b013e328342b8ad.
• [2]J. Geundo, H. Y. Dok, K. Shin, H. L. Dae. et al.(2011). Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma. Korean Journal of Hematology.46:103-110. DOI: 10.1097/CCO.0b013e328342b8ad.
• [3]N. Mounier, C. Gisselbrecht. (2011). Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era. Current Opinion in Oncology.23(2):209-213. DOI: 10.1097/CCO.0b013e328342b8ad.
• [4]C. R. Flowers, R. Sinha, J. M. Vose. (2010). Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer Journal for Clinicians.60(6):393-408. DOI: 10.1097/CCO.0b013e328342b8ad.
• [5]F. Cabanillas. (2010). Front-line management of diffuse large B cell lymphoma. Current Opinion in Oncology.22(6):642-645. DOI: 10.1097/CCO.0b013e328342b8ad.
• [6]N. Brousse, A. Jarry, B. Cerf. (1991). Les lymphomes du tissu lymphoïde annexé aux muqueuses. Lymphomes non Hodgkiniens:167-174. DOI: 10.1097/CCO.0b013e328342b8ad.
• [7]B. Coiffier. (1993). Prognostic factors in non-Hodgkin's lymphomas. Therapeutic implications. Revue du Praticien.43(13):1640-1643. DOI: 10.1097/CCO.0b013e328342b8ad.
• [8]B. A. Gofardy. (1991). Etude rétrospective des LMNH du massif facial supérieur. Actualité des carcinologies cervico-faciales:161-168. DOI: 10.1097/CCO.0b013e328342b8ad.
• [9]L. H. Sehn, B. Berry, M. Chhanabhai, C. Fitzgerald. et al.(2007). The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood.109(5):1857-1861. DOI: 10.1097/CCO.0b013e328342b8ad.
• [10]P. J. Shenoy, K. Bumpers, N. King. (2009). Black/white difference in the treatment and outcomes of diffuse large B cell lymphoma: a matched cohort analysis. Blood.114, abstract 1392. DOI: 10.1097/CCO.0b013e328342b8ad.
• [11]C. Gisselbrecht. (1993). Lymphomes agressifs. Revue du Praticien.43(13):1648-1653. DOI: 10.1097/CCO.0b013e328342b8ad.
• [12]M. E. Hardly, S. H. Swan, E. A. Holly. (1998). Temporal trends in the incidence of non Hodgkin's lymphoma and selected malignancies in a population with the high of acquired immunodeficiency syndrom (AIDS). American Journal of Epidemiology.128:261-267. DOI: 10.1097/CCO.0b013e328342b8ad.
• [13]G. Matthew, M. Brower, S. Mandlia. (2000). Changes in acquired immunode immunodeficiency syndrome-related lymphoma since the introduction of hightly active antiretroviral therapy. Blood.96:2730-2734. DOI: 10.1097/CCO.0b013e328342b8ad.
• [14]N. Hashimoto, K. Kurihara. (1982). Pathological characteristics of oral lymphomas. Journal of Oral Pathology.11(3):214-227. DOI: 10.1097/CCO.0b013e328342b8ad.
• [15]P. J. Stowing, A. R. M. Wittkamp, P. M. Kluin, P. C. M. Wilde. et al.(1985). Extranodal non Hodgkin's lymphoma of the oral tissues. Journal of Maxillofacial Surgery.13:85-92. DOI: 10.1097/CCO.0b013e328342b8ad.
• [16]M. A. Bekadja, S. Zouani. Résultats préliminaires du protocole CHOP dans les lymphomes non hodgkiniens agressifs de l’adulte : corrélation avec les index pronostiques. . DOI: 10.1097/CCO.0b013e328342b8ad.
• [17]N. A. Parfrey, R. B. Mann, S. E. Selonick, W. E. Beschorner. et al.(1985). Malignant large cell lymphoma of B-cell type with multilobated nuclei. Report of a case and review of the literature. Cancer.55(9):1913-1917. DOI: 10.1097/CCO.0b013e328342b8ad.
• [18]S. A. Peleri, S. Dirnohofer, S. Ascani, E. Sabaltini. et al.(2002). Diffuse large B cell lymphoma: one or more entities? Present controversies and possible tools for its sub classification. Histopathology.41:482-509. DOI: 10.1097/CCO.0b013e328342b8ad.
• [19]E. Brusamolino. (2009). First-line therapy of CD20+ diffuse large B-cell lymphoma: facts and open questions. Haematologica.94(9):1194-1198. DOI: 10.1097/CCO.0b013e328342b8ad.
• [20]H. Tilly, M. Dreyling. (2010). Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology.21(5):172-174. DOI: 10.1097/CCO.0b013e328342b8ad.
• [21]B. Coiffier, C. Thieblemont, E. Van Den Neste, G. Lepeu. et al.(2010). Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood.116(12):2040-2045. DOI: 10.1097/CCO.0b013e328342b8ad.